Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM-TMI in Addition to Standard Conditioning for Haploidentical Transplantation in Acute Leukemia and MDS
NCT04187105Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of Illinois Chicago. Primary endpoint: Graft-Versus-Host Disease-Free, Relapse-Free Survival at 1 year. Started Jan 2020; status: recruiting.
Beyond the preview
Go deeper on NCT04187105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187105.